← Back to Search

SSRI

Study of Vilazodone to Treat Social Anxiety Disorder

N/A
Waitlist Available
Led By Michael R. Liebowitz, MD
Research Sponsored by The Medical Research Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study endpoint: minimum 6 weeks - maximum 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

The purpose of this study is to determine whether Vilazodone is effective in the treatment of symptoms of Social Anxiety Disorder among adults.

Eligible Conditions
  • Social Anxiety Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study endpoint: minimum 6 weeks - maximum 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and study endpoint: minimum 6 weeks - maximum 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Liebowitz Social Anxiety Scale (LSAS) - total score
Secondary study objectives
Change in Hamilton Anxiety scale total
Change in Hamilton Depression scale total
Change in the Clinical Global Impression of Severity of Illness score
+3 more

Side effects data

From 2017 Phase 4 trial • 24 Patients • NCT01999920
46%
Lightheadedness
46%
Increased Appetite
46%
Headache
38%
Dry Mouth
38%
Insomnia
38%
Impaired Concentration
31%
Diarrhea/Gas
31%
Sexual Dysfunction (women)
31%
Nausea
31%
Decreased Appetite
23%
Restlessness
23%
Fatigue
23%
Heartburn
23%
Apathy
15%
Excessive Sweating
15%
Somnolence
15%
Decreased Libido (men)
15%
Sexual Dysfunction (men)
8%
Tremor
8%
Forgetfulness
8%
Blurry Vision
8%
Skin Problems
8%
Impaired Coordination
8%
Decreased Libido (women)
8%
Constipation
8%
Nervousness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vilazodone
Placebo

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: VilazodoneExperimental Treatment1 Intervention
Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vilazodone
FDA approved

Find a Location

Who is running the clinical trial?

The Medical Research NetworkLead Sponsor
5 Previous Clinical Trials
280 Total Patients Enrolled
Forest LaboratoriesIndustry Sponsor
337 Previous Clinical Trials
89,164 Total Patients Enrolled
Michael R. Liebowitz, MDPrincipal InvestigatorThe Medical Research Network, LLC
1 Previous Clinical Trials
63 Total Patients Enrolled
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top